Glenmark Pharmaceuticals Ltd. has launched Winlevi® (clascoterone 10 mg/g cream) across several European markets, marking the company’s first New Chemical Entity (NCE) launch in the region.
The product has been introduced through Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of the company, and represents a milestone in Glenmark’s strategy to expand its specialty dermatology portfolio.
Shares of Glenmark Pharmaceuticals were trading at ₹2,160.10, up 0.73%, giving the company a market capitalization of ₹60,966.66 crore.
Rollout across key European markets
The company said Winlevi has been launched in:
- Nordic countries
- Central and Eastern Europe
- Spain
Launches in Portugal and other markets are being pursued through strategic partnerships.
The rollout follows the European Commission’s approval granted in October 2025 to Cassiopea S.p.A., a subsidiary of Cosmo N.V., for the treatment of acne vulgaris in adults and adolescents aged between 12 and below 18 years.
First new topical acne therapy in decades
Winlevi contains clascoterone, the first commercially available topical androgen receptor inhibitor.
The treatment works locally within sebaceous glands to reduce:
- Sebum production
- Inflammation
According to the company, it does so without producing systemic anti-androgen effects.
Winlevi is also the first new topical acne treatment introduced in more than 40 years with a first-in-class mechanism of action.
Large patient base
The launch targets a broad market, with acne remaining one of the most common skin conditions.
Industry estimates cited by the company indicate:
- More than 95% of males experience acne during adolescence.
- Around 85% of females are affected.
- Nearly half continue to experience acne into adulthood.
Focus on specialty medicines
Glenmark said the launch reflects its strategy of bringing differentiated therapies to patients across global markets.
The company plans to expand the product’s reach in Europe through a mix of:
- Direct commercial operations
- Strategic partnerships
Commenting on the launch, Jiri Havranek, Group Vice President and Business Head – Europe, said the rollout strengthens Glenmark’s branded dermatology business and demonstrates its ability to execute multi-country launches.
Shift toward higher-value products
The launch supports Glenmark’s broader push into specialty pharmaceuticals, a segment that typically offers stronger margins and greater brand recognition than traditional generic medicines.
About the company
Glenmark Pharmaceuticals operates in more than 80 countries and has businesses spanning branded formulations, specialty products, generics and consumer healthcare.
The company runs:
- 11 manufacturing facilities
- Six R&D centres
Its key therapeutic areas include:
- Respiratory diseases
- Dermatology
- Oncology
TL;DR
Glenmark has launched Winlevi acne cream across several European markets, marking its first New Chemical Entity launch in Europe. The product, containing clascoterone, is the first new topical acne treatment with a novel mechanism introduced in over four decades.
AI summary
- Glenmark launched Winlevi across key European markets.
- It is the company’s first NCE launch in Europe.
- Winlevi contains clascoterone, a topical androgen receptor inhibitor.
- The product targets acne vulgaris in adults and adolescents.
- The launch strengthens Glenmark’s specialty dermatology business.






